Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SLC6A15 | Q9H2J7 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27777004 | 0.85 | P2RX4 (0.39) | MAPTL3MBTL1KDM4EPOLBGRM5 | |
| SCHEMBL28536825 | 0.83 | LMNA (0.39) | MAPTLMNAGPR119L3MBTL1KDM4E | |
| SCHEMBL852448 | 0.82 | POLB (0.43) | GPR119POLBGRM5GRM1 | |
| SCHEMBL6034220 | 0.79 | GRM5 (0.41) | MAPTLMNAGPR119L3MBTL1KDM4E | |
| SCHEMBL2558541 | 0.79 | MYC (0.36) | MAPTLMNAL3MBTL1KDM4ENPSR1 | |
| SCHEMBL6110761 | 0.78 | P2RX4 (0.46) | LMNANPSR1ALDH1A1TSHRP2RX4 | |
| SCHEMBL1836164 | 0.77 | PARP1 (0.36) | MAPTLMNAKDM4EKCNH2TSHR | |
| SCHEMBL30511570 | 0.77 | PARP1 (0.36) | MAPTLMNAKDM4EKCNH2TSHR | |
| SCHEMBL29106412 | 0.77 | SMN1; SMN2 (0.33) | MAPTLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29106429 | 0.76 | SMN1; SMN2 (0.33) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735320-B1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2009-06-17 | — | — | EP | disclosed |
| US-7470705-B2 | e.g. Cis-4-[acety1-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-methoxy-3,4-dihydro-2H- [1,5]naphthyridine-1-carboxylic acid isopropyl ester; cholesterol ester transfer protein (CETP) inhibitors; increasing plasma HDL- cholesterol, decreasing plasma LDL- cholesterol; atherosclerosis | ELI LILLY AND COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-20070173526-A1 | Compounds and methods for treating dyslipidemia | ELI LILLY AND COMPANY (US) | 2007-07-26 | — | — | US | disclosed |
| EP-1735320-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097806-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173526-A1 | Compounds and methods for treating dyslipidemia | PCSK9, APOB, LIPC | MAPT 4690/4885LMNA 439/4885GPR119 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.